PASG
Passage Bio, Inc.NASDAQHealthcare$8.76+8.42%ClosedMarket Cap: $28.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.48
P/S
0.00
EV/EBITDA
-0.14
DCF Value
$6.70
FCF Yield
-112.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-135.0%
ROA
-73.1%
ROIC
-100.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-7.7M | $-13.0M | $-4.08 | — |
| FY 2025 | $0.00 | -Infinity% | $-43.2M | $-45.5M | $-14.35 | — |
| Q3 2025 | $0.00 | NaN% | $-8.7M | $-7.7M | $-2.45 | — |
| Q2 2025 | $0.00 | -Infinity% | $-10.3M | $-9.4M | $-2.96 | — |
| Q1 2025 | $0.00 | NaN% | $-16.5M | $-15.4M | $-4.96 | — |
| Q4 2024 | $0.00 | -Infinity% | $-14.3M | $-12.7M | $-4.10 | — |
| FY 2024 | $0.00 | NaN% | $-70.4M | $-64.8M | $-21.44 | — |
| Q3 2024 | $0.00 | NaN% | $-20.7M | $-19.3M | $-6.26 | — |
| Q2 2024 | $0.00 | NaN% | $-17.4M | $-16.0M | $-5.18 | — |
| Q1 2024 | $0.00 | NaN% | $-18.1M | $-16.7M | $-5.94 | — |
| Q4 2023 | $0.00 | NaN% | $-18.4M | $-16.8M | $-6.10 | — |
| FY 2023 | $0.00 | -Infinity% | $-100.1M | $-102.1M | $-37.29 | — |